Aelis Farma S.A. (id:10831 AELIS)
2.90 EUR
Opening hours: 09:00 - 17:30 (Central European Standard Time: 11/28/2024 1:40:55 AM)
Exchange closed, opens in 7 hours 19 minutes
1.40 EUR (1.40%)
-2.03 EUR (-2.03%)
-22.04 EUR (-22.04%)
-78.03 EUR (-78.03%)
-78.36 EUR (-78.36%)
-78.52 EUR (-78.52%)
About Aelis Farma S.A.
Market Capitalization 42.33M
Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is headquartered in Bordeaux, France.
| Headquarters (address) |
146 rue Lafaurie de Monbadon Bordeaux 33 000 France |
| Phone | 33 5 54 54 23 27 |
| Website | https://www.aelisfarma.com |
| Employees | 26 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | AELIS |
| Exchange | European Stock Exchange |
| Currency | EUR |
| 52 week range | 2.78 - 13.60 |
| Market Capitalization | 42.33M |
| P/E forward | 0.464 |
| Price/Sale | 3.93 |
| Price/Book | 3.92 |
| Beta | 0.206 |
| EPS | -0.530 |
| EPS France (ID:70, base:331) | 3.06 |